Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Teva Pharmaceutical Industries stock | $9.41

Own Teva Pharmaceutical Industries stock in just a few minutes.

Fact checked

Teva Pharmaceutical Industries Limited is a drug manufacturers-specialty & generic business based in the US. Teva Pharmaceutical Industries shares (TEVA) are listed on the NYSE and all prices are listed in US Dollars. Teva Pharmaceutical Industries employs 40,039 staff and has a trailing 12-month revenue of around USD$16.7 billion.

How to buy shares in Teva Pharmaceutical Industries

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Teva Pharmaceutical Industries. Find the stock by name or ticker symbol: TEVA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Teva Pharmaceutical Industries reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$9.41, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Teva Pharmaceutical Industries, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Teva Pharmaceutical Industries. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Teva Pharmaceutical Industries share price

Use our graph to track the performance of TEVA stocks over time.

Teva Pharmaceutical Industries shares at a glance

Information last updated 2021-01-12.
Latest market closeUSD$9.41
52-week rangeUSD$6.25 - USD$13.56
50-day moving average USD$10.1509
200-day moving average USD$10.1635
Wall St. target priceUSD$11.82
PE ratio 872
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.004

Buy Teva Pharmaceutical Industries shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Teva Pharmaceutical Industries stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Teva Pharmaceutical Industries price performance over time

Historical closes compared with the close of $9.41 from 2020-10-16

1 week (2021-01-08) N/A
1 month (2020-12-15) N/A
3 months (2020-10-19) 1.29%
6 months (2020-07-17) -23.87%
1 year (2020-01-15) N/A
2 years (2019-01-15) N/A
3 years (2018-01-15) N/A
5 years (2016-01-15) N/A

Is Teva Pharmaceutical Industries under- or over-valued?

Valuing Teva Pharmaceutical Industries stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Teva Pharmaceutical Industries's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Teva Pharmaceutical Industries's P/E ratio

Teva Pharmaceutical Industries's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 872x. In other words, Teva Pharmaceutical Industries shares trade at around 872x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Teva Pharmaceutical Industries's PEG ratio

Teva Pharmaceutical Industries's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7256. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Teva Pharmaceutical Industries's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Teva Pharmaceutical Industries's EBITDA

Teva Pharmaceutical Industries's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$4.6 billion.

The EBITDA is a measure of a Teva Pharmaceutical Industries's overall financial performance and is widely used to measure a its profitability.

Teva Pharmaceutical Industries financials

Revenue TTM USD$16.7 billion
Operating margin TTM 18.19%
Gross profit TTM USD$7.5 billion
Return on assets TTM 3.54%
Return on equity TTM -32.82%
Profit margin -24.18%
Book value $8.753
Market capitalisation USD$11.9 billion

TTM: trailing 12 months

Shorting Teva Pharmaceutical Industries shares

There are currently 32.7 million Teva Pharmaceutical Industries shares held short by investors – that's known as Teva Pharmaceutical Industries's "short interest". This figure is 2.2% up from 32.0 million last month.

There are a few different ways that this level of interest in shorting Teva Pharmaceutical Industries shares can be evaluated.

Teva Pharmaceutical Industries's "short interest ratio" (SIR)

Teva Pharmaceutical Industries's "short interest ratio" (SIR) is the quantity of Teva Pharmaceutical Industries shares currently shorted divided by the average quantity of Teva Pharmaceutical Industries shares traded daily (recently around 8.0 million). Teva Pharmaceutical Industries's SIR currently stands at 4.1. In other words for every 100,000 Teva Pharmaceutical Industries shares traded daily on the market, roughly 4100 shares are currently held short.

However Teva Pharmaceutical Industries's short interest can also be evaluated against the total number of Teva Pharmaceutical Industries shares, or, against the total number of tradable Teva Pharmaceutical Industries shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Teva Pharmaceutical Industries's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Teva Pharmaceutical Industries shares in existence, roughly 30 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Teva Pharmaceutical Industries shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Teva Pharmaceutical Industries.

Find out more about how you can short Teva Pharmaceutical Industries stock.

Teva Pharmaceutical Industries's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Teva Pharmaceutical Industries.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Teva Pharmaceutical Industries's total ESG risk score

Total ESG risk: 58.8

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Teva Pharmaceutical Industries's overall score of 58.8 (as at 01/01/2019) is pretty weak – landing it in it in the 76th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Teva Pharmaceutical Industries is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Teva Pharmaceutical Industries's environmental score

Environmental score: 77.02/100

Teva Pharmaceutical Industries's environmental score of 77.02 puts it squarely in the 87th percentile of companies rated in the same sector. This could suggest that Teva Pharmaceutical Industries is a laggard in its sector in terms of its environmental impact, and exposed to a greater level of risk.

Teva Pharmaceutical Industries's social score

Social score: 47.2/100

Teva Pharmaceutical Industries's social score of 47.2 puts it squarely in the 58th percentile of companies rated in the same sector. This could suggest that Teva Pharmaceutical Industries is pretty average in terms of looking after its workforce and social impact.

Teva Pharmaceutical Industries's governance score

Governance score: 65.26/100

Teva Pharmaceutical Industries's governance score puts it squarely in the 81st percentile of companies rated in the same sector. That could suggest that Teva Pharmaceutical Industries is a laggard in its sector in terms of responsible leadership, and exposed to a greater level of risk.

Teva Pharmaceutical Industries's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Teva Pharmaceutical Industries scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Teva Pharmaceutical Industries hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Teva Pharmaceutical Industries Limited was last rated for ESG on: 2019-01-01.

Total ESG score 58.8
Total ESG percentile 76.26
Environmental score 77.02
Environmental score percentile 87.16
Social score 47.2
Social score percentile 58.24
Governance score 65.26
Governance score percentile 80.64
Level of controversy 3

Teva Pharmaceutical Industries share dividends

We're not expecting Teva Pharmaceutical Industries to pay a dividend over the next 12 months.

Have Teva Pharmaceutical Industries's shares ever split?

Teva Pharmaceutical Industries's shares were split on a 2:1 basis on 1 July 2004. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Teva Pharmaceutical Industries shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Teva Pharmaceutical Industries shares which in turn could have impacted Teva Pharmaceutical Industries's share price.

Teva Pharmaceutical Industries share price volatility

Over the last 12 months, Teva Pharmaceutical Industries's shares have ranged in value from as little as $6.25 up to $13.56. A popular way to gauge a stock's volatility is its "beta".

TEVA.US volatility(beta: 1.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Teva Pharmaceutical Industries's is 1.4958. This would suggest that Teva Pharmaceutical Industries's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Teva Pharmaceutical Industries overview

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site